Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Pamela B. Allen, Latifa Bazzi, Bin Zhang, Qing Chen, Liron Barnea Slonim, Hatice Savas, Ranjana H. Advani, Andrew M Evens, Barbara Pro, Reem Karmali, Eric Mou, Robert Eisner, Robert Bayer, Leo I. Gordon, Jane N. Winter

Blood (2024) 144 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2024-208680

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci

Blood (2024) 144 (Supplement 1): 860.

https://doi.org/10.1182/blood-2024-199212

Published: 2024

Journal Articles

Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Shengqin Su, Ajay Subramanian, Timothy Flerlage, Jamie E. Flerlage, Cedric Rossi, Troy Noordenbos, Joseph G. Schroers-Martin, Everett J. Moding, Richard T. Hoppe, Ranjana H. Advani, Yasodha Natkunam, Ash A. Alizadeh, Michael S. Binkley

Blood (2024) 144 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2024-212013

Published: 2024

Journal Articles

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2024-206398

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas

Daniella Klebaner, Natalie Park, Mallika Marar, Matthew J. Frank, Susan Hiniker, Richard T. Hoppe, Joseph G. Schroers-Martin, Ranjana H. Advani, Ash A. Alizadeh, Sushma Bharadwaj, David B. Miklos, Saurabh Dahiya, Michael S. Binkley

Blood (2024) 144 (Supplement 1): 7130.

https://doi.org/10.1182/blood-2024-200930

Published: 2024

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Tetiana Skrypets, Onder Alpdogan, Luana Conte, Monica Civallero, Athina Lymboussaki, Julie M. Vose, Ivan Dlouhy, Maria Elena Cabrera, Felicitas Hitz, Sabela Bobillo, Won Seog Kim, Arnon Nagler, Dario Marino, Ranjana H. Advani, Caterina Stelitano, Pierluigi Porcu, Massimo Federico

Blood (2024) 144 (Supplement 1): 6402.

https://doi.org/10.1182/blood-2024-203976

Published: 2024

Journal Articles

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Michael Leukam, Matthew Weinstock, Jon E. Arnason, Ranjana H. Advani

Blood (2024) 144 (Supplement 1): 6284.

https://doi.org/10.1182/blood-2024-206520

Published: 2024

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Maria Sureda Balari, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Ozcan, Amos Odeleye-Ajakaye, Nishitha Reddy, Patricia Marinello, Jane N. Winter

Blood (2023) 142 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2023-181171

Published: 2023

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma

Shengqin Su, Ajay Subramanian, Timothy Flerlage, Jamie E. Flerlage, Stefan K. Alig, Everett J. Moding, Richard T. Hoppe, Ranjana H. Advani, Yasodha Natkunam, Ash A. Alizadeh, Michael S. Binkley

Blood (2023) 142 (Supplement 1): 3016.

https://doi.org/10.1182/blood-2023-180288

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muffly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen-Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai

Blood (2023) 141 (22): 2727–2737.

https://doi.org/10.1182/blood.2022018827

Published: 2023

Includes: Supplemental data

NARROW

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only